Company SANA AB

Stocks

SANION

SE0005794617

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 20/07/2026 BST			5-day change	1st Jan Change
12.94 ^SEK	-0.77%		-4.08%	-38.96%

07-16	Syria seizes weapons hidden in tanker truck, says cargo was for Hezbollah	RE
07-06	France's Macron visits Syria, in first trip by an EU head of state since Assad toppled	RE

Business description: SANA AB

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Number of employees: 43

Sales by Activity: SANA AB

Fiscal Period: December	2021 (SEK)	2022 (SEK)	2023 (SEK)	2024 (SEK)	2025 (SEK)
Biotechnology	10.48M	15.28M	16.84M	335M	434M

See all business segments

Geographical breakdown of sales: SANA AB

Fiscal Period: December	2021 (SEK)	2022 (SEK)	2023 (SEK)	2024 (SEK)	2025 (SEK)
Ireland	-	-	-	-	405M
Germany	-	-	8.72M	17.68M	10.01M
Denmark	-	-	633K	555K	9.6M
United Kingdom	-	-	7.49M	16.25M	7.54M
USA	2.5M	3.76M	-	300M	2.49M
Other European Countries	7.97M	11.52M	-	-	-

See all geographic segments

Executive Committee: SANA AB

Manager	Title	Age	Since
Janus Schreiber Larsen COO	Chief Operating Officer	54	28/02/2025
Thomas Feldthus CEO	Chief Executive Officer	66	29/04/2022
Palle Christophersen CTO	Chief Tech/Sci/R&D Officer	68	31/12/2013
Johnny Stilou DFI	Director of Finance/CFO	59	11/05/2025
Pierandrea Muglia CTO	Chief Tech/Sci/R&D Officer	60	09/03/2025

See SANA AB governance

Composition of the Board of Directors: SANA AB

Director	Title	Age	Since
Jørgen Drejer CHM	Chairman	71	29/04/2022
Carl Johan Bertil Sundberg BRD	Director/Board Member	68	31/12/2014
Anna Ljung BRD	Director/Board Member	46	18/01/2018
John Sørensen Haurum CHM	Chairman	63	30/04/2025

Composition of the Board of Directors

Shareholders: SANA AB

Name	Stocks	%	Valuation
NORDEA BANK ABP 2.436 %	3,362,136	2.436 %	5 M kr
Joakim Tedrof 1.829 %	2,524,529	1.829 %	3 M kr
Dan Peters 1.703 %	2,350,000	1.703 %	3 M kr
Jørgen Drejer 1.505 %	2,077,083	1.505 %	3 M kr
Handelsbanken Fonder AB 1.336 %	1,844,732	1.336 %	2 M kr

List of SANA AB shareholders

Company details: SANA AB

Saniona AB

Murervangen 42

2600, Glostrup

+45 70 70 52 25

http://www.saniona.com

Group companies: SANA AB

Name	Category and Sector
Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Engages in research and experimental development on natural sciences and engineering	Miscellaneous Commercial Services

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SANA AB	-0.77%	-4.08%	+47.89%	+33.40%	184M
ARGENX SE	+0.21%	-0.79%	+53.17%	+57.39%	53.79B
WUXI APPTEC CO., LTD.	+5.37%	+3.31%	+50.39%	+83.65%	54.69B
INSMED INCORPORATED	-1.20%	-1.94%	+4.35%	+402.68%	23.2B
BIONTECH SE	+0.74%	+2.32%	-16.23%	-14.44%	23.31B
WUXI BIOLOGICS (CAYMAN) INC.	+0.21%	+0.37%	+36.93%	-5.80%	20.03B
GENMAB A/S	-1.18%	-2.97%	+30.12%	-33.30%	17.31B
PHARMAESSENTIA CORPORATION	-1.67%	-6.00%	+163.95%	+284.69%	14.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.83%	+0.32%	+32.36%	+570.87%	15.36B
EXELIXIS, INC.	-0.70%	-0.91%	+24.87%	+179.47%	13.96B
Average	+0.02%	-1.05%	+42.78%	+155.86%	23.68B
Weighted average by Cap.	+0.97%	-0.93%	+41.85%	+133.12%